PCN71 COST-EFFECTIVENESS (CE) ANALYSIS OF ERBB2-TARGETED THERAPIES IN WOMEN WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2+ METASTATIC BREAST CANCER (MBC) AND LIMITED EXPOSURE TO PRIOR CHEMOTHERAPY (CT)
PCN9 VALIDITY OF PROPORTIONAL HAZARDS (PH) WEIBULL MODELS FOR ANALYZING PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2+ (HER2+) METASTATIC BREAST CANCER (MBC) RECEIVING LAPATINIB PLUS CAPECITABINE (L+C) VERSUS CAPECITABINE ONLY (C-ONLY)
PCN27 AN ANALYSIS OF COSTS ASSOCIATED WITH ADMINISTRATION OF TRASTUZUMAB-BASED COMBINATION IV THERAPIES IN METASTATIC BREAST CANCER PATIENTS IN A US POPULATION
Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.
Autorzy:
Latimer NR; School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom. Bell H; School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom. Abrams KR; Department of Health Sciences, University of Leicester, Leicester, United Kingdom. AmonkarMM; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. Casey M; Pfizer, Collegeville, Pennsylvania.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2016 May; Vol. 5 (5), pp. 806-15. Date of Electronic Publication: 2016 Jan 27.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Psychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies